Comparison of overall survival of adult and pediatric osteosarcoma patients using the national cancer database.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
BACKGROUND: Differences in overall survival (OS) between pediatric and adult patients diagnosed with osteosarcoma are poorly understood. The objective of this study is to compare the OS of pediatric and adult patients with osteosarcoma, identify prognostic factors associated with OS, and explore factors specifically associated with pediatric osteosarcoma using data gathered from the National Cancer Database (NCDB). METHODS: Patients > = 1 years old and diagnosed with osteosarcoma between 2004 and 2017 were included in the study. Multivariable Cox regression analysis adjusted for gender, race, income, education, place of living, health insurance status, year of diagnosis, stage of cancer, surgery, chemotherapy, and radiation therapy (RT) was used to assess the association of age with the OS of the patients. RESULTS: The analysis included 8,458 patients among whom 3,027 (35.8%) were between 1 and 17 years old. In the multivariable Cox regression analysis, adult patients had worse OS compared with pediatric patients (HR: 1.84; p < .01). When stratified by treatment type, pediatric patients had better OS in several groups. This includes those who received chemotherapy alone (HR: 0.58, p < .01), surgery alone (HR: 0.48, p < .01), surgery plus chemotherapy (HR: 0.56, p < .01), and those who received no treatment (HR: 0.31, p < .01). There was no significant difference in OS between pediatric and adult patients receiving a combination of chemotherapy, surgery, and RT (HR: 0.81, p = .42). In analysis stratified by cancer stage, pediatric patients had better OS compared to adult patients at each stage. Multivariable logistic regression analysis revealed that pediatric patients are more likely to be non-white, have insurance, present with unknown/occult stage disease, have poorly differentiated tumors, and receive chemotherapy, or surgery. Additionally, multivariable Cox regression analysis identified factors associated with improved OS: age, diagnosis between 2011 and 2015, private insurance, non-metastatic disease, well-differentiated tumors, and receiving chemotherapy or surgery, but not RT. CONCLUSION: Pediatric patients diagnosed with osteosarcoma had better OS compared to their adult counterparts. Pediatric patients had better OS compared to adults when the analysis was stratified by treatment modality and stage of cancer. Further research is necessary to elucidate the underlying reason for this difference.